Vyriad Raises Additional $25M for Clinical-Stage Genetic Therapies

Vyriad concludes final tranche of $25 million to its Series B financing, bringing total round to $85 million, supporting imminent first-in-human testing of VV169.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here